Cardioprotective effects of minocycline against doxorubicin-induced cardiotoxicity

Yazdan Naderi1, Sara Khosraviani2, Saba Nasiri3

  • 1Cellular and Molecular Research Center, Research Institute for Prevention of Non-communicable Disease, Qazvin University of Medical Sciences, Qazvin, Iran.

Abstract

Insights

Minocycline (Min) protects against Doxorubicin (Dox)-induced heart damage by reducing inflammation and oxidative stress. This study shows Min is a potential therapeutic agent to mitigate Dox cardiotoxicity.

Area of Science:

  • Cardiology
  • Pharmacology
  • Toxicology

Background:

  • Doxorubicin (Dox) chemotherapy is limited by cardiotoxicity.
  • Inflammation, oxidative stress, and apoptosis are key mechanisms in Dox-induced cardiotoxicity.
  • Minocycline (Min) possesses anti-inflammatory, anti-oxidant, and anti-apoptotic properties.

Purpose of the Study:

  • To evaluate the cardioprotective effects of Min against Dox-induced cardiotoxicity in a rat model.
  • To investigate the underlying mechanisms of Min's protective action.

Main Methods:

  • Adult male rats were divided into control, Dox, Min (45 and 90 mg/kg), and Dox + Min groups.
  • Dox was administered for two weeks; Min was administered for three weeks.
  • Cardiac tissue and serum were analyzed for histological changes, enzyme activities (LDH, CK-MB), oxidative stress markers (catalase, SOD, MDA), and inflammatory cytokines (TNF-α, IL-1β).

Main Results:

  • Min treatment significantly reduced serum LDH and CK-MB levels compared to the Dox group.
  • Min increased cardiac antioxidant enzyme activities (catalase, SOD) and decreased lipid peroxidation (MDA).
  • Min significantly lowered cardiac TNF-α and IL-1β levels and improved histopathological findings.

Conclusions:

  • Minocycline effectively reduces Doxorubicin-induced cardiotoxicity in rats.
  • The cardioprotective effects of Min are attributed to its potent anti-oxidant and anti-inflammatory properties.

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
672
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
482
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
25